DDX53 and neoplasm: Importantly, the CT26+NIH3T3‐LV‐VTN group demonstrated a 12.93% lower tumor suppression rate than the CT26+NIH3T3‐LV‐VEC group (Figures 7B,C; Figure S9A, Supporting Information), indicating a relative resistance of VTN‐expressing tumors to aPD1 therapy in CRC.